In the grand, six-month-long tradition of Oncology for the Inquisitive Mind, Josh and Michael provide an update from an international meeting to keep you right up to date with the latest and greatest developments in their field. This week's special is the ASCO GI Symposium, held in Moscone, California, and brought to your ears from Melbourne. From two guys in their pyjamas. Who would much rather be in Moscone, California.

At any rate, updates abound in this OftiM special. Listen on so you too can crest the wave of Gastrointestinal Oncology!

Studies Discussed: NAPOLI 3, CHECKMATE 648 and 649 updates, SPOTLIGHT, Pemigatinib in FGFR mutant mCRC

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncology for the Inquisitive Mind returns to its regular broadcasting schedule and discusses metastatic renal cell cancer (ccRCC). As not to be outdone, Josh takes a cultural tangent exploring the world of opera after seeing "The Hours" broadcast through Met: Live in HD. While Josh doesn't sing this episode, he highlights this opera's parallels with cancer patients undergoing treatment. To avoid losing sight of this podcast's purpose, Michael and Josh soon find their way. They discovered that metastatic renal cell carcinoma has many treatment options, including targeted therapy, immunotherapy, or even combining these two modalities! Tune in to find out where the evidence currently stands.

Links to studies discussed in this episode (subscription may be required):

CHECKMATE 214: https://www.nejm.org/doi/full/10.1056/nejmoa1712126

KEYNOTE-426: https://www.nejm.org/doi/full/10.1056/NEJMoa1816714 

Other studies of interest:

CLEAR: https://www.nejm.org/doi/full/10.1056/NEJMoa2035716

CheckMate 9ER: https://www.nejm.org/doi/full/10.1056/nejmoa2026982

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

This is OncoSnacks, a new, fortnightly OftIM spinoff!

In this new bite-sized series, Michael and Josh try to sink their teeth into more slice-of-life topics, all to help you, our beloved listeners, digest some of the most common problems your patients will serve to you on a platter. This week, a treatment side effect that actually stops people eating (and making lame food-based puns as well): mucositis.

This common side effect of anti-cancer systemic therapy can have a major impact on patients quality of life, frequently leading to hospitalisations, significant morbidity and nasogastric tubes galore. But how do we manage such a troublesome problem? Listen on to find out!

eviQ reference guide on mucositis: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/oropharyngeal/210-oral-mucositis-and-stomatitis

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

This week on Oncology for the Inquisitive Mind, Michael dons his cultural hat and begins with an Ode to the Kidneys, organs that are as much a muse for poets worldwide as the heart (probably). However, you didn't come to this podcast for excellent poetry being delivered with all the panache and misguided enthusiasm of a walrus stepping on a piece of LEGO, and Michael and Josh aim to deliver on this front. Our intrepid pair examine the controversial world of adjuvant treatment of clear cell renal cell cancers (ccRCC), an area of research littered with the ghosts of negative or equivocal studies. But, not every study can be a FLAURA or a DESTINY, and negative studies are just as important, so listen on to find out exactly what NOT to do. Truly, an OftIM first!

Links to studies discussed in this episode (subscription may be required):

ASSURE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591751/

KEYNOTE-564: https://www.nejm.org/doi/full/10.1056/NEJMoa2106391

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

As the southern hemisphere basks in summer's beautiful warmth, Michael and Josh skip the beach to explore skin cancer. While melanoma usually takes centre stage in the oncological world, it is far less common than basal cell carcinoma or squamous cell carcinoma. Metastatic squamous cell carcinoma now has a viable and effective treatment option called cemiplimab. At the other end of the spectrum, Michael investigates the very rare cancer type Merkle Cell Carcinoma and how Avelumab has changed its treatment paradigm. Once again, it's immunotherapy at its best. So remember, while listening to our podcast, don't forget to wear a hat and apply sunscreen generously!

Links to studies discussed in this episode (subscription may be required):

Migden et al. (Cemiplimab): https://www.nejm.org/doi/10.1056/NEJMoa1805131?url_ver=Z39.88

JAVELIN Merkel 200 (Cohort B): https://jitc.bmj.com/content/9/7/e002646

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

New year, new episode of Oncology for the Inquisitive Mind! After enjoying their holiday break, Josh and Michael dive right into 2023 with an episode especially aimed at trainees just about to start their new professional journey in Medical Oncology. Joined by an old friend, the wise-beyond-his-years Dr Andrew Jensen, they discuss life as a trainee, balancing work and life, and how to navigate the tough first few years of life in training, which can so often feel like being a bottle cast into a storm. Join us for an episode that may be light on hazard ratios and p values, but heavy on practical tips and wisdom, delivered in the tone of three dads drinking beer by a campfire...

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.

Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.

On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.

Links to studies discussed in this episode (subscription may be required):

BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltext

Keynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549

Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

"I'm not in danger; I AM the danger!" So said Bryan Cranston's Walter White, and so too said early-stage lung cancer when confronted with adjuvant chemotherapy (maybe). In this episode, however, Josh and Michael follow in the footsteps of Hank Schrader, Steve Gomez et al., discussing ways to tackle one of the biggest killers in oncology. While we may not have found a way to control early-stage lung cancer, new developments are on the horizon, such as neoadjuvant chemo-immunotherapy and adjuvant osimertinib. So listen on, with the disclaimer that any similarities between Walter White and Jane Eyre are purely coincidental, no matter what Josh may argue...

Links to studies discussed in this episode (subscription may be required):

CHECKMATE-816: https://www.nejm.org/doi/10.1056/NEJMoa2202170

ADAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Mikey travel back millions of years to a time when dinosaurs roamed the Earth, as recent research has demonstrated, unmolested by cancer. Then they come crashing back to the present to discuss this week's topic, metastatic colorectal cancer. Will they discover secrets hidden across the aeons? Was the secret to cancer treatment hidden in the bones of our scaled precursors? No, of course not. But there will be a lot of information on the improving treatment of colorectal cancer, which has not taken millions of years to advance. Oh, and Michael does a passable Richard Attenborough.

Links to studies discussed in this episode (subscription may be required):

FIRE-3: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltext

KEYNOTE 177: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

BEACON: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075

Epidemiological Study of Tumours in Dinosaurs: https://link.springer.com/article/10.1007/s00114-003-0473-9

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Movember is an important event focussing on men's health, including cancer. Prostate cancer is the most common male cancer diagnosed in Australia and the second most common in American men. To highlight this and explore the pioneering treatments available, Michael and Josh interviewed the esteemed Dr Megan Crumbaker. Megan is a medical oncologist specialising in genitourinary cancer and works at The Kinghorn Cancer Centre and St. Vincents Health in Sydney, Australia. Dr Crumbaker completed her undergraduate at Rice University, Texas, before completing her medical training in Sydney and a PhD in prostate genomics through The Garvan Research Institute.

We discussed all things prostate oncology with Megan, including research, career, pioneering treatment options and all things prostate cancer. These treatment pearls are not to be missed by any budding oncologist!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.